US 12,150,945 B2
Liver disease
Mahesh V. Patel, Salt Lake City, UT (US); Nachiappan Chidambaram, Sandy, UT (US); Satish K. Nachaegari, Holladay, UT (US); Burke Byrne, Salt Lake City, UT (US); Kilyoung Kim, West Jordan, UT (US); and Jonathan A. Baker, Salt Lake City, UT (US)
Filed by Lipocine Inc., Salt Lake City, UT (US)
Filed on Jul. 19, 2019, as Appl. No. 16/517,533.
Claims priority of provisional application 62/701,309, filed on Jul. 20, 2018.
Claims priority of provisional application 62/714,968, filed on Aug. 6, 2018.
Claims priority of provisional application 62/728,580, filed on Sep. 7, 2018.
Claims priority of provisional application 62/783,190, filed on Dec. 20, 2018.
Claims priority of provisional application 62/793,724, filed on Jan. 17, 2019.
Prior Publication US 2020/0155570 A1, May 21, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/568 (2006.01); A61K 31/201 (2006.01); A61K 31/355 (2006.01); A61K 45/06 (2006.01); A61P 1/16 (2006.01); G01N 33/92 (2006.01)
CPC A61K 31/568 (2013.01) [A61K 31/201 (2013.01); A61K 31/355 (2013.01); A61P 1/16 (2018.01); G01N 33/92 (2013.01); A61K 45/06 (2013.01); G01N 2800/085 (2013.01); G01N 2800/52 (2013.01)] 30 Claims
 
1. A method of treating a fatty liver condition comprising orally administering a pharmaceutical composition to a subject having hepatocellular ballooning, wherein said pharmaceutical composition includes a testosterone ester component (TEC) consisting essentially of testosterone dodecanoate (TD), said TEC being in an amount of about 200 mg to about 750 mg when said subject is male and said TEC being in an amount of about 1/10th- 1/15th of about 200 mg to about 750 mg when said subject is female, and wherein in response to said administration, said hepatocellular ballooning is resolved, and wherein said hepatocellular ballooning resolution comprises a reduction of hepatocellular ballooning in said subject by at least one NAS point.